盤中異動 | 泰格醫藥盤中上漲7%,報於74.5港元
2022年5月11日11時54分,泰格醫藥(HK03347)盤中上漲7%,報於74.5港元,成交額達3803.88萬港元,換手率達到0.42%。
5月10日訊,泰格醫藥(03347)發佈公告,董事會認爲公司2019年限制性股票激勵計劃預留部分的第二個限售期解除限售條件已經成就,同意辦理50名激勵對象約35.81萬股限制性股票的解除限售事宜。本次解除限售股份可上市流通日爲2022年5月13日。
4月29日,麥格理:泰格醫藥(03347)評級升至“跑贏大市”,目標價降至88.6港元。4月27日,野村:維持泰格醫藥(03347)“買入”評級,目標價降至115.13港元。3月14日,野村:維持泰格醫藥(03347)“買入”評級,目標價下調至134.75港元。
最新的財務數據顯示,公司於2022年1季度,營業收入18.18億人民幣,淨利潤5.74億人民幣;營業收入同比增加101.55%,毛利潤同比增加66.79%,淨利潤同比減少20.56%。
盈立趨勢長盈模型最近一次交易信號,2022年4月21日出現觀望信號,觸發價格爲83.75港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.